Literature DB >> 11111211

Adenosine triphosphate for cardioversion of supraventricular tachycardia in two hydropic fetuses.

J H Dangel1, T Roszkowski, K Bieganowska, K Kubicka, J Ganowicz.   

Abstract

OBJECTIVE: We performed a retrospective study to check the effectiveness of adenosine triphosphate (Striadyne) for cardioversion of fetal supraventricular tachycardia (SVT) and to evaluate neonatal outcome after prenatal treatment of severe SVT with fetal hydrops.
METHODS: Two hydropic fetuses with SVT were treated with Striadyne injection into the umbilical vein, as an additional treatment to the digoxin given intravenously to the mother. Both fetuses were in severe condition, with ultrasound, Doppler and laboratory signs of fetal distress and congestive heart failure.
RESULTS: Sinus rhythm was obtained in both cases for different periods of time, without side effects of Striadyne. The children survived. There were severe cardiac and neurologic problems after delivery.
CONCLUSIONS: Striadyne was an effective drug in converting SVT to the sinus rhythm in hydropic fetuses. Digoxin was useless in these fetuses in spite of the therapeutic level which was obtained in both mothers. We suppose that fetal SVT causing fetal hydrops could be the reason of brain damage, and intensive antiarrhythmic treatment seemed to be necessary. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11111211     DOI: 10.1159/000021030

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  2 in total

Review 1.  Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia.

Authors:  Isabelle Malhamé; Christy Gandhi; Gofran Tarabulsi; Matthew Esposito; Kristin Lombardi; Antony Chu; Kenneth K Chen
Journal:  Obstet Med       Date:  2018-11-15

2.  Management of Fetal Tachyarrhythmias.

Authors:  Gautam K. Singh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.